Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas.
OBJECTIVE
The management of adult patients with grade 2 gliomas remains a challenge for the clinical neuro-oncologist. Several clinical prognostic factors appear to be as important as treatment factors in determining outcome. From the European Organisation for Research and Treatment of Cancer (EORTC) trials 22844 and 22845, a prognostic scoring system has been proposed based on the presence of unfavourable prognostic factors. The aim of the present study was to assess the additional prognostic value of (11)C-methionine (MET) measured by positron emission tomography (PET) in the setting of the EORTC prognostic scoring system.


METHODS
In this retrospective review, 129 patients with supratentorial grade 2 gliomas were subjected to a PET study as part of the pre-treatment tumour investigation. One hundred and three cases were classified as low-risk patients (0-2 unfavourable factors) and 26 cases as high-risk patients (3-5 unfavourable factors) according to the EORTC criteria. MET PET was evaluated as an extra prognostic factor in both groups.


RESULTS
In the high-risk group, patients with high MET uptake had a worse outcome than patients with low MET uptake. A similar trend was found for the low-risk group in patients with oligodendrocytic tumours.


CONCLUSIONS
Our findings further strengthen the role of MET PET as an important prognostic tool in the management of this group of patients.
Smits
A
A
Department of Neuroscience, Neurology, University Hospital, 751 85, Uppsala, Sweden. anja.smits@neurologi.uu.se
Westerberg
E
E
Ribom
D
D
D000293:Adolescent; D000328:Adult; D000368:Aged; D002250:Carbon Radioisotopes; D005910:Glioma / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery; D006801:Humans; D008715:Methionine / Q000737:chemistry* / Q000378:metabolism; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011184:Postoperative Period; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk; D012955:Societies, Medical; D015996:Survival Rate
D002250:Carbon Radioisotopes; D008715:Methionine
Cancer. 2001 Sep 15;92 (6):1541-9
11745233
J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
11895036
Br J Neurosurg. 2002 Dec;16(6):573-7
12617239
Cancer. 1994 Sep 15;74(6):1784-91
8082081
Acta Radiol. 1987 May-Jun;28(3):225-9
2958026
Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9
10571199
J Neurosurg. 2001 Nov;95(5):735-45
11702861
J Clin Oncol. 2002 May 1;20(9):2267-76
11980997
J Clin Oncol. 2002 Apr 15;20(8):2076-84
11956268
J Neurosurg. 2006 Feb;104(2):238-53
16509498
Onkologie. 2004 Jun;27(3):246-50
15249713
Neurology. 1998 May;50(5):1316-22
9595980
Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56
8948338
Neurology. 2002 Jul 9;59(1):40-8
12105305
J Neurosurg. 2001 Nov;95(5):746-50
11702862
Neurology. 2002 Jul 9;59(1):121-3
12105319
Eur J Nucl Med Mol Imaging. 2002 May;29(5):632-40
11976801
Curr Opin Neurol Neurosurg. 1992 Dec;5(6):924-31
1334739
Semin Oncol. 2003 Dec;30(6 Suppl 19):23-8
14765381
Acta Neuropathol. 2005 Jan;109(1):93-108
15685439
Neurology. 2000 Apr 11;54(7):1442-8
10751254
Neurology. 2001 May 22;56(10):1285-90
11376174
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24
11872276
J Nucl Med. 1998 May;39(5):778-85
9591574